Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder

• Published in: Biological psychiatry (1969) Vol. 93; no. 12; pp. 1099 - 1107
• Main Authors: Holmes, Sophie E., Asch, Ruth H., Davis, Margaret T., DellaGioia, Nicole, Pashankar, Neha, Gallezot, Jean-Dominique, Nabulsi, Nabeel, Matuskey, David, Sanacora, Gerard, Carson, Richard E., Blumberg, Hilary P., Esterlis, Irina
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.06.2023
• Subjects: Bipolar Disorder; Depression; Depressive Disorder, Major; Glutamate; Humans; Imaging; Magnetic Resonance Imaging; mGluR5; PET; Positron-Emission Tomography - methods; Prefrontal Cortex - metabolism; Receptor, Metabotropic Glutamate 5 - metabolism; Bipolar disorder; Depression; Glutamate; mGluR5; Imaging; PET
• ISSN: 0006-3223; 1873-2402; 1873-2402
• DOI: 10.1016/j.biopsych.2022.10.018

Understanding the neurobiology underlying bipolar disorder (BD) versus major depressive disorder (MDD) is crucial for accurate diagnosis and for driving the discovery of novel treatments. A promising target is the metabotropic glutamate receptor 5 (mGluR5), a modulator of glutamate transmission associated with synaptic plasticity. We measured mGluR5 availability in individuals with MDD and BD for the first time using positron emission tomography. Individuals with BD (n = 17 depressed; n = 10 euthymic) or MDD (n = 17) and healthy control (HC) individuals (n = 18) underwent imaging with [18F]FPEB positron emission tomography to quantify mGluR5 availability in regions of the prefrontal cortex, which was compared across groups and assessed in relation to depressive symptoms and cognitive function. Prefrontal cortex mGluR5 availability was significantly different across groups (F6,116 = 2.18, p = .050). Specifically, mGluR5 was lower in BD versus MDD and HC groups, with no difference between MDD and HC groups. Furthermore, after dividing the BD group, mGluR5 was lower in both BD-depression and BD-euthymia groups versus both MDD and HC groups across regions of interest. Interestingly, lower dorsolateral prefrontal cortex mGluR5 was associated with worse depression in MDD (r = −0.67, p = .005) but not in BD. Significant negative correlations were observed between mGluR5 and working memory in MDD and BD-depression groups. This work suggests that mGluR5 could be helpful in distinguishing BD and MDD as a possible treatment target for depressive symptoms in MDD and for cognitive alterations in both disorders. Further work is needed to confirm differentiating roles for mGluR5 in BD and MDD and to probe modulation of mGluR5 as a preventive/treatment strategy.